A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib
Phase 1/2
120
about 5.4 years
18–120
1 site in MD
What this study is about
This trial is testing a combination of sacituzumab govitecan and berzosertib in people with advanced small cell lung cancer or other cancers that are resistant to PARP inhibitors. The goal is to see if this treatment can shrink tumors and determine the safe dosage for this new treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Berzosertib
- 2.Take Sacituzumab Govitecan
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
sacituzumab govitecan
Primary: Phase I: MTD, Phase II: ORR
Secondary: Duration of response, Overall survival (OS), Progression free survival (PFS), Safety and tolerability, Toxicity grade and type
Oncology